| Literature DB >> 25901601 |
Mohamed Abd El Rahman1, Denise Haase2, Axel Rentzsch2, Julia Olchvary2, Hans-Joachim Schäfers3, Wolfram Henn4, Stefan Wagenpfeil5, Hashim Abdul-Khaliq2.
Abstract
BACKGROUND: In asymptomatic Marfan syndrome (MFS) patients we evaluated the relationship between the types of fibrillin-1 (FBN1) gene mutation and possible altered left ventricular (LV) function as assessed by three-dimensional speckle tracking echocardiography (3D-STE). METHODS ANDEntities:
Mesh:
Substances:
Year: 2015 PMID: 25901601 PMCID: PMC4406686 DOI: 10.1371/journal.pone.0124112
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and clinical characteristics of the study population.
| Variable | Marfan | Controls | p-value |
|---|---|---|---|
| Age | 24.82±15.44 | 20.13±7.81 | 0.262 |
| Male | 26 | 28 | 0.184 |
| Height (cm) | 173.99±22.18 | 168.55±14.50 | 0.020 |
| Weight (kg) | 18.50±29.15 | 60.95±16.33 | 0.224 |
| BSA (m2) | 1.70±0.45 | 1.64±0.27 | 0.224 |
| Heart rate (bpm) | 73.60±13.74 | 67.26±12.73 | 0.027 |
| Systolic blood pressure (mm Hg) | 115.12±19.06 | ||
| Diastolic blood pressure(mm Hg) | 66.45±10.13 | ||
| Mitral valve prolapse | 16 | ||
| Mild mitral regurgitation | 14 | ||
| Mild aortic regurgitation | 13 | ||
| Aortic valve ring diameter (mm) | 22.61±4.10 | 21.28±3.19 | 0.180 |
| Aortic root diameter (mm) | 34.12±9.35 | 26.07±3.63 | 0.0001 |
| ST junction diameter (mm) | 26.73±7.26 | 20.55±3.60 | 0.002 |
| ß blocker treatment | 9 | ||
| ARB treatment | 29 |
Abbreviations: BSA: body surface area, ST: sino-tubular, ARB: angiotensin receptor blocker.
Left ventricular function among Marfan syndrome patients (MFS) and controls evaluated by conventional echocardiography.
| Variable | MFS patients | Controls | p-value |
|---|---|---|---|
| M-mode LV EDD (mm) | 9.79±2.56 | 9.19±1.58 | 0.291 |
| M-mode LV ESD (mm) | 31.98±8.14 | 30.33±4.13 | 0.511 |
| LV FS (%) | 37.33±7.05 | 37.31±4.35 | 0.686 |
| MAPSE (mm) | 17.31±3.31 | 19.00±2.49 | 0.005 |
| LV E/A ratio | 1.68±0.65 | 2.09±0.57 | 0.001 |
| LV ICT (ms.) | 46.18± 22.18 | 43.05±15.82 | 0.581 |
| LV IVRT (ms.) | 29.91±23.33 | 42.77±24.13 | 0.019 |
| LV Tei index | 0.25±0.11 | 0.28±0.09 | 0.247 |
| Aortic VTI (cm) | 25.37±11.91 | 27.06±4.66 | 0.001 |
Abbreviations: LV: left ventricle, EDD: end-diastolic dimension, ESD: end-systolic dimension, FS: fractional shortening, MAPSE: mitral annular plane systolic excursion, E: early diastolic, A: late diastolic, ICT: isovolumetric contraction time, IVRT: isovolumetric relaxation time, VTI: velocity time integral.
Left ventricular function among Marfan syndrome patients (MFS) and controls as evaluated by 3-D echocardiography.
| Variable | MFS patients | Controls | p-value |
|---|---|---|---|
| LV EDV/BSA (ml/m2) | 77.34 ±24.19 | 64.95±7.73 | 0.012 |
| LV ESV/BSA (ml/m2) | 33.95±15.67 | 24.94±4.92 | 0.005 |
| LV EF (%) | 57.43±7.51 | 62.69±4.76 | 0.000 |
| LV CO (l/min) | 5.05±1.85 | 4.41±0.91 | 0.173 |
| LV global longitudinal strain (%) | 14.85±2.89 | 17.90±2.01 | 0.000 |
| LV global circumferential strain (%) | 13.93±2.81 | 16.82±2.17 | 0.000 |
| LV global area strain (%) | 25.76±4.43 | 30.51±2.61 | 0.000 |
| LV global radial strain (%) | 38.66±8.77 | 47.41±5.85 | 0.000 |
Abbreviations: LV: left ventricle, EDV: end-diastolic volume, ESV: end-systolic volume, BSA: body surface area, EF: ejection fraction, CO: cardiac output.
Fig 1The reduced LV systolic function as assessed by three-dimensional echocardiography is related to the severity of gene mutation.
LVEF: Left ventricular ejection fraction
Fig 2The reduced LV circumferential and not longitudinal systolic deformation as assessed by three-dimensional speckle tracking echocardiography is related to the severity of gene mutation.
3-D: Three-dimensional echocardiography, STE: Speckle tracking echocardiography.
Fig 3For prediction of severe gene mutation, the area under the ROC curve was 0.838 for global 3D derived LV circumferential strain and 0.790 for global 3D derived area strain.
Left atrial function among Marfan syndrome patients (MFS) and controls evaluated by 3-D echocardiography.
| Variable | MFS patients | Controls | p-value |
|---|---|---|---|
| LA EDV/BSA (ml/m2) | 11.77 ±7.23 | 7.71±2.14 | 0.001 |
| LA ESV/BSA (ml/m2) | 25.84±10.78 | 22.0±6.34 | 0.323 |
| LA kick volume (ml/m2) | 28.46±21.15 | 18.55±7.55 | 0.040 |
| LA reservoir function (%) | 39.59 ±13.49 | 47.32±12.65 | 0.003 |
| LA pump function (%) | 26.85±9.78 | 30.37±7.51 | 0.102 |
| LA EF (%) | 55.95±10.26 | 62.79±12.00 | 0.000 |
Abbreviations: LA: left atria, EDV: end-diastolic volume, ESV: end-systolic volume, BSA: body surface area, EF: ejection fraction.